Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (15 Mio. €): Immune-Image: Spezifische Bildgebung der Immunzelldynamik mit neuartigen Tracer-Strategien Hor01.10.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Immune-Image: Spezifische Bildgebung der Immunzelldynamik mit neuartigen Tracer-Strategien
Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and inflammatory diseases. Although immunotherapeutics are effective not all patients benefit and side effects vary greatly. Thus, there is an unmet need for a personalized approach. Blood and tissue biomarkers have played only a modest role up until now in assessing immune status in vivo and we believe that non-invasive whole body imaging will make a significant contribution in the future. Although the field of imaging (PET, MRI, Optical Imaging) is flourishing, its application to patient immune status measurement and monitoring has barely been explored. Within Immune-Image we aim to develop new immunotracers for imaging specific immune cell subsets, develop quantitative imaging workflows, validate the immunotracers pre-clinically in relevant disease models, produce the tracers in a Good Manufacturing Practice (GMP)-compliant way, and conduct smart clinical trials, including with novel tracers. To this end, insights will be gained into the optimal use of drugs and a more efficient development of immunotherapeutics. Moreover, the success rate of immunotherapy development will be enhanced since our molecular imaging platform will provide novel insights into patient immune status, which will support drug development and treatment decisions. To achieve our goals, we have assembled an experienced international multi-disciplinary consortium composed of chemists, biologists, immunologists, physicists, pharmacists, information technologists, and medical specialists with diverse and essential backgrounds who will join forces to design, synthesise, evaluate and validate immunotracers and create sustainable molecular imaging techniques that can be broadly applied in the assessment of the immune status and immune modulation of patients. There will be input from patients and regulators in order to assure optimal design and execution of immunotracer clinical trials.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Academisch Ziekenhuis Groningen | 2.174.208 € |
| Antaros Medical AB | 250.000 € |
| BAYER AG | 0,00 € |
| 0,00 € | |
| Commissariat a L Energie Atomique et aux Energies Alternatives | 510.000 € |
| EBERHARD KARLS UNIVERSITAET TUEBINGEN | 1.103.496 € |
| European Cancer Patient Coalition | 100.000 € |
| F. HOFFMANN-LA ROCHE AG | 0,00 € |
| Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca | 514.560 € |
| 433.310 € | |
| Imaginab Inc. | 0,00 € |
| Janssen Pharmaceutica N.V. | 0,00 € |
| 400.000 € | |
| NOVARTIS PHARMA AG | 0,00 € |
| Pfizer Ltd. | 0,00 € |
| Stichting Amsterdam UMC | 3.993.722 € |
| Stichting Lygature | 450.000 € |
| TAKEDA PHARMACEUTICALS INTERNATIONAL AG | 0,00 € |
| Takeda Development Centre Europe Ltd. | 0,00 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 1.041.875 € |
| 400.000 € | |
| UNIVERSITAET MUENSTER | 1.930.000 € |
| Universite Paris-Saclay | 0,00 € |
| VIB VZW | 885.000 € |
| Vrije Universiteit Brussel | 813.829 € |
Quelle: https://cordis.europa.eu/project/id/831514
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "Academisch Ziekenhuis Groningen - EU-Förderung (15 Mio. €): Immune-Image: Spezifische Bildgebung der Immunzelldynamik mit neuartigen Tracer-Strategien"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
